This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tandem Diabetes (TNDM) Q1 Net Loss Narrows, Guidance Up
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong international and domestic pump sales and shipment boosted the first-quarter top line.
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 53.33% and 14.98%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care, Inc. (TNDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tandem Diabetes Care, Inc. (TNDM) Down 13.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Stock
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and shipments.
4 Stocks in Focus as Diabetes Sector Grows Amid Pandemic
by Debanjana Dey
Here are a few diabetes-centric MedTech stocks, ABT, NVO, MDT, PODD and TNDM, which investors can focus on to reap profits in the new normal.
Tandem (TNDM) Grows on Abbott, Dexcom Pacts Amid COVID-19 Woes
by Zacks Equity Research
Tandem Diabetes (TNDM) is expects t:sport to be a major growth catalyst for 2022.
Tandem Diabetes' (TNDM) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic and international pump sales and shipments boosted the Q4 top line.
Tandem Diabetes Care, Inc. (TNDM) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Stock
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and shipments.
Tandem Diabetes' (TNDM) Insulin Pump Approved by Health Canada
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology cleared for use in Canada post the receipt of Health Canada approval.
Tandem Diabetes (TNDM) Q3 Earnings Miss, '20 Sales View Up
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.
Zacks.com featured highlights include: The New York Times, Apple and Tandem Diabetes Care
by Zacks Equity Research
Zacks.com featured highlights include: The New York Times, Apple and Tandem Diabetes Care
3 Stocks to Watch Closely for Superb Earnings Acceleration
by Tirthankar Chakraborty
At present, the New York Times (NYT), Apple (AAPL) and Tandem Diabetes Care (TNDM) are some of the few companies boasting solid earnings acceleration.
Abbott's Libre 3 Receives CE Mark, Boosts CGM Prospects
by Zacks Equity Research
Abbott's (ABT) environment-friendly next-generation FreeStyle Libre 3 system aims to provide a better quality of life to diabetics in Europe at the same affordable price of previous systems.
Insulet (PODD) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Insulet (PODD) is optimistic about maintaining growth momentum of its Omnipod system along with tapping the booming diabetes market.
3 Stocks to Buy From Strong MedTech Spaces Amid the Pandemic
by Debanjana Dey
Here are three stocks from three sub-sectors from MedTech that have held their ground despite the pandemic-led market mayhem.
4 Best Diabetes Device Stocks to Focus on Amid Coronavirus Crisis
by Debanjana Dey
Here are a few diabetes-centric MedTech stocks that investors can focus on to reap profits amid the pandemic-battered stock market situation.
Medicare Coverage for Libre 2 Boosts Abbott's CGM Prospects
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 2 iCGM is now available to Medicare-eligible diabetic patients via CMS' reimbursement expansion.
Tandem Diabetes' Advanced Insulin Pump Study Results Favorable
by Zacks Equity Research
Per the DCLP5 study, Tandem Diabetes' (TNDM) insulin pump with Control-IQ technology suitable for use in children aged six to 13 years, which has been published in the NEJM.
Medtronic Plans New Acquisition in AI-Driven Diabetes Care
by Zacks Equity Research
Medtronic's (MDT) acquisition of Companion Medical aims to expand service to diabetics using multiple daily injections for diabetes management.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Tandem Diabetes (TNDM) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.
3 Large-Cap MedTech Stocks to Buy on Northbound Market Trend
by Sriparna Ghosal
Backed by an upward trend of share prices and projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.
Abbott, Tandem Diabetes Seal Deal on Diabetes Management
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre CGM technology to be integrated with Tandem Diabetes' insulin pumps to enhance diabetes care.